Bioxytran, Inc. (the “Company”) is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s approach potentially will result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians.
Company profile
Ticker
BIXT
Exchange
Website
CEO
David Platt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERICA'S DRIVING RANGES, INC., U.S. Natural Nutrients & Minerals, Inc., U.S. RARE EARTH MINERALS, INC, U.S. RARE EARTH MINERALS, INC.
SEC CIK
Corporate docs
Subsidiaries
As of October 5, 2017, Bioxytran, Inc. ...
IRS number
262797630
BIXT stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
19 Apr 24
8-K
Material Modifications to Rights of Security Holders
19 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
424B4
Prospectus supplement with pricing info
2 Oct 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
28 Sep 23
S-1/A
IPO registration (amended)
26 Sep 23
UPLOAD
Letter from SEC
26 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Hoberman Alan M | common | Grant | Acquire A | No | No | 0.142 | 70,423 | 10.00 k | 1,009,422 |
19 Apr 24 | Conaway Dale H | common | Grant | Acquire A | No | No | 0.142 | 70,423 | 10.00 k | 936,122 |
27 Mar 24 | Hoberman Alan M | common | Grant | Acquire A | No | No | 0.114 | 266,955 | 30.43 k | 928,776 |
27 Mar 24 | Platt David | common | Grant | Acquire A | Yes | No | 0.104 | 439,595 | 45.72 k | 20,133,018 |